On this page

HYDROCORTISONE VALERATE

Prescription ANDA TE AB Official labelling
Informational index, not medical advice. Content is reproduced from public FDA and NLM data. Always confirm against the manufacturer's current prescribing information. Report adverse events to FDA MedWatch.

Overview

Brand name
HYDROCORTISONE VALERATE
Generic name
Hydrocortisone Valerate
Dosage form
Cream
Route
Topical
Marketing category
ANDA · ANDA
Labeler
Lupin Pharmaceuticals, Inc.
Product type
Human Prescription Drug
DEA schedule
Not scheduled
Active ingredients
1
NDC product codes
3
Packages
9
Data completeness
76% of corroborating sources present

Active ingredients

Source: NDC Directory
Active ingredients and strengths as listed in the NDC Directory.
Ingredient Strength RxCUI Monograph
Hydrocortisone Valerate 2 mg/g 1370754 View

Forms, strengths and routes

Source: NDC Directory
Dosage form
Cream
Route of administration
Topical
Presentations
12

Pharmacologic classes are listed in the class section below.

Pharmacologic class

Source: NDC Directory
Established pharmacologic classes (EPC), mechanisms of action (MoA), chemical structures (CS) and physiologic effects (PE).
Class Type Browse
Corticosteroid Hormone Receptor Agonists [MoA] MoA All 215 members
Corticosteroid [EPC] EPC All 215 members

Regulatory status

Source: Drugs@FDANDC Directory
Application number
210307
Application type
ANDA · Abbreviated New Drug Application
Approval date
August 15, 2019
Sponsor
LUPIN
Products on application
1
Submissions recorded
1
Products approved under application 210307.
Product Trade name Form Strength Ingredient Status TE Flags
210307-001 HYDROCORTISONE VALERATE CREAM HYDROCORTISONE VALERATE Prescription AB

Therapeutic equivalence

Source: Orange Book
TE code
AB
Reference Listed Drug
No
Reference Standard
No

What this rating means: Therapeutically equivalent — bioequivalence demonstrated by in vivo or in vitro testing

Codes beginning with “A” indicate products the FDA considers therapeutically equivalent. Codes beginning with “B” indicate bioequivalence has not been established. See methodology.

Approval history

Source: Drugs@FDA
Most recent submissions on application 210307.
Type No. Action Status Date Review
Original application 1 Approved August 15, 2019 Standard

Prescribing information

Source: openFDA Drug Labeling

Reproduced verbatim from the Structured Product Labeling submitted to the FDA (effective 20251113). This is the manufacturer's labelling text, not a summary and not advice.

HUMAN PRESCRIPTION DRUG · 20251113 HUMAN PRESCRIPTION DRUG · 20231129

Indications and Usage

openFDA Drug Labeling

INDICATIONS AND USAGE Hydrocortisone valerate cream USP, 0.2% is a medium potency corticosteroid indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid responsive dermatoses in adult patients.

Dosage and Administration

openFDA Drug Labeling

DOSAGE AND ADMINISTRATION Hydrocortisone valerate cream USP, 0.2% should be applied to the affected area as a thin film two or three times daily depending on the severity of the condition. As with other corticosteroids, therapy should be discontinued when control is achieved. If no improvement is seen within 2 weeks, reassessment of the diagnosis may be necessary. Hydrocortisone valerate cream USP, 0.2% should not be used with occlusive dressings unless directed by a physician. Hydrocortisone valerate cream USP, 0.2% should not be applied in the diaper area if the patient requires diapers or plastic pants as these garments may constitute occlusive dressing.

Contraindications

openFDA Drug Labeling

CONTRAINDICATIONS Hydrocortisone valerate cream USP, 0.2% is contraindicated in those patients with a history of hypersensitivity to any of the components of the preparation.

Adverse Reactions

openFDA Drug Labeling

ADVERSE REACTIONS The following local adverse reactions have been reported with topical corticosteroids, and they may occur more frequently with the use of occlusive dressings. These reactions are listed in an approximate decreasing order of occurrence: burning, itching, irritation, dryness, folliculitis, hypertrichosis, acneiform eruptions, hypopigmentation, perioral dermatitis, allergic contact dermatitis, maceration of the skin, secondary infection, skin atrophy, striae, and miliaria. In controlled clinical studies involving pediatric patients one month to 2 years of age (n=29), the incidence of adverse experiences, regardless of relationship to the use of hydrocortisone valerate cream USP, 0.2%, was approximately 21%. Reported reactions included stinging (10%), eczema (7%), fungal infection (3%), and gastrointestinal disorder (3%). In controlled clinical studies involving pediatric patients 2 to 12 years of age (n=153), the incidence of adverse experiences, regardless of relationship to the use of hydrocortisone valerate cream USP, 0.2%, was approximately 10%. Reported reactions included stinging (3%), burning skin (2%), infection (Body as a Whole) (2%). Skin irritation, eczema, pruritus, application site reaction, rash, rash maculopapular, and dry skin were all reported at incidences of approximately 1%. To report SUSPECTED ADVERSE REACTIONS, contact Cosette Pharmaceuticals, Inc. at 1-800-922-1038 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

Description

openFDA Drug Labeling

DESCRIPTION Hydrocortisone valerate cream USP, 0.2% contains hydrocortisone valerate, 11,2l-dihydroxy-17-[(l-oxopentyl)oxy]-(11β)-pregn-4-ene-3,20-dione, a synthetic corticosteroid for topical dermatologic use. The corticosteroids constitute a class of primarily synthetic steroids used topically as anti-inflammatory and antipruritic agents. Chemically, hydrocortisone valerate is C 26 H 38 O 6 . It has the following structural formula: Hydrocortisone valerate has a molecular weight of 446.58. It is a white to off white, crystalline powder, soluble in ethanol, chloroform and acetone, slightly soluble in isopropanol and insoluble in water. Each gram of hydrocortisone valerate cream USP, 0.2% contains 2mg hydrocortisone valerate in a hydrophilic base composed of carbomer 980, dibasic sodium phosphate, methylparaben, polyoxyl 2 stearyl ether, propylene glycol, purified water, sodium lauryl sulfate, steareth-100, stearyl alcohol and white petrolatum. chem-structure

OVERDOSAGE Topically applied hydrocortisone valerate cream USP, 0.2% can be absorbed in sufficient amounts to produce systemic effects (see PRECAUTIONS ).

How Supplied / Storage and Handling

openFDA Drug Labeling

HOW SUPPLIED Hydrocortisone valerate cream USP, 0.2%, is supplied in 15 g (NDC 68180-954-01), 45 g (NDC 68180-954-02) and 60 g (NDC 68180-954-03) tube sizes. Storage Store at 25°C (77°F); excursions permitted to 15° to 30°C (59° to 86°F) [see USP Controlled Room Temperature]. LUPIN and the are registered trademarks of Lupin Pharmaceuticals, Inc. Image

Adverse event reports

Source: openFDA FAERS
614
FAERS reports mentioning this drug
as of 2026-09-25T03:42:24+00:00
A report count is not a risk measure. FAERS accepts voluntary and mandatory reports without establishing causation, and reporting is influenced by how widely a drug is used, how long it has been marketed, and media attention. FDA states that reports “do not prove that the drug caused the event”. Compare rates, not totals.

Attributed to this product's most-reported active ingredient: HYDROCORTISONE VALERATE. Combination products with more than six active ingredients are not attributed, because a report count summed across a long ingredient list measures the list, not the medicine.

Packaging and NDCs

Source: NDC Directory
Every National Drug Code package associated with this medication. The NDC is the identifier used for dispensing, billing and pharmacovigilance in the United States.
Package NDC Product NDC Labeler Description Marketing start
0713-0720-15 0713-0720 Cosette Pharmaceuticals, Inc. 1 TUBE in 1 CARTON (0713-0720-15) / 15 g in 1 TUBE July 1, 2021
0713-0720-37 0713-0720 Cosette Pharmaceuticals, Inc. 1 TUBE in 1 CARTON (0713-0720-37) / 45 g in 1 TUBE July 1, 2021
0713-0720-60 0713-0720 Cosette Pharmaceuticals, Inc. 1 TUBE in 1 CARTON (0713-0720-60) / 60 g in 1 TUBE July 1, 2021
68180-954-01 68180-954 Lupin Pharmaceuticals, Inc. 1 TUBE in 1 CARTON (68180-954-01) / 15 g in 1 TUBE November 19, 2019
68180-954-02 68180-954 Lupin Pharmaceuticals, Inc. 1 TUBE in 1 CARTON (68180-954-02) / 45 g in 1 TUBE November 19, 2019
68180-954-03 68180-954 Lupin Pharmaceuticals, Inc. 1 TUBE in 1 CARTON (68180-954-03) / 60 g in 1 TUBE November 19, 2019
51672-1290-1 51672-1290 Sun Pharmaceutical Industries, Inc. 1 TUBE in 1 CARTON (51672-1290-1) / 15 g in 1 TUBE August 25, 1998
51672-1290-3 51672-1290 Sun Pharmaceutical Industries, Inc. 1 TUBE in 1 CARTON (51672-1290-3) / 60 g in 1 TUBE August 25, 1998
51672-1290-6 51672-1290 Sun Pharmaceutical Industries, Inc. 1 TUBE in 1 CARTON (51672-1290-6) / 45 g in 1 TUBE August 25, 1998
0713-0720 0713-0720 Cosette Pharmaceuticals, Inc. — July 1, 2021
68180-954 68180-954 Lupin Pharmaceuticals, Inc. — November 19, 2019
51672-1290 51672-1290 Sun Pharmaceutical Industries, Inc. — August 25, 1998

Sources for this page

Every dataset that contributed a fact to this page.
Dataset Agency Used for
NDC Directory FDA Identity, ingredients, strengths, forms, routes, labelers, packages
Drugs@FDA FDA Application, sponsor, submissions, review documents, marketing status
Orange Book FDA Therapeutic equivalence codes, reference drug flags, patents, exclusivity
Drug Labeling FDA / NLM Prescribing information reproduced above
FAERS FDA Adverse event report counts

Generated September 25, 2026 · 12 sections on this page.